研究概要
负载索拉非尼的NKEM在体外显示出杀伤甲状腺癌细胞的能力,甚至对ATC也有效。这为药物递送系统和甲状腺癌治疗提供了新机会。
研究思路结论见上方概要
背景
外泌体已成为治疗和识别许多疾病的潜在纳米技术领域。然而,外泌体的生成是一个困难、耗时且产量低的过程。与此同时,外泌体模拟物(EM)在特性上与外泌体相似,但具有更高的产量。本研究的目的是生产负载索拉非尼的自然杀伤(NK)细胞来源的EM(NKEM),并测试其对甲状腺癌细胞系的杀伤能力。
方法
索拉非尼在NKEM生产过程中通过与NK细胞混合被载入NKEM(NKEM-S)。随后,用纳米颗粒追踪分析(NTA)对这两种纳米颗粒进行表征以测量其粒径。此外,利用共聚焦激光显微镜和生物发光成像(BLI)技术研究了NKEM-S对甲状腺癌细胞系的细胞摄取和体外杀伤效果。
结果
观察到甲状腺癌细胞对NKEM和NKEM-S的摄取。此外,BLI证实了NKEM-S对两种甲状腺癌细胞系的杀伤和抗增殖作用。尤为重要的是,NKEM-S即使对未分化甲状腺癌(ATC)细胞也表现出理想的杀伤效果。
展开英文摘要原文
BACKGROUND: Exosomes have become a potential field of nanotechnology for the treatment and identification of many disorders. However, the generation of exosomes is a difficult, time-consuming, and low-yielding procedure. At the same time, exosome mimetics (EM) resemble exosomes in their characteristics but have higher production yields. The aim of this study was to produce natural killer (NK) cell-derived EM (NKEM) loaded with sorafenib and test their killing ability against thyroid cancer cell lines.
MATERIALS AND METHODS: Sorafenib was loaded into NKEM by mixing sorafenib with NK cells during NKEM production (NKEM-S). Then, these two types of nanoparticles were characterized with nanoparticle tracking analysis (NTA) to measure their sizes. In addition, the cellular uptake and in vitro killing effect of NKEM-S on thyroid cancer cell lines were investigated using confocal laser microscopy and bioluminescence imaging (BLI) techniques.
RESULTS: The uptake of NKEM and NKEM-S by the thyroid cancer cells was observed. Moreover, BLI confirmed the killing and anti-proliferation effect of NKEM-S on two thyroid cancer cell lines. Especially important, the NKEM-S demonstrated a desirable killing effect even for anaplastic thyroid cancer (ATC) cells.
CONCLUSION: Sorafenib-loaded NKEM showed the ability to kill thyroid cancer cells in vitro, even against ATC. This provides a new opportunity for drug delivery systems and thyroid cancer treatment.
论文信息
- 作者
- Zhu L、Ahn BC
- 单位
- Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea.South Korea
- 期刊
- Experimental oncology2025 Feb 20